|
|
|
|
|
|
|
|
|
|
|
|
|
19.10.26 - 12:01
|
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, Ms. Monahan will lead Zymeworks' commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease (COPD), following the Company's recent acquisition of Theravance Biopharma....
|
|
|
|
|
|
|
|
|
|
|
23.09.26 - 22:01
|
Zymeworks Completes Acquisition of Theravance Biopharma (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks' strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows....
|
|
|
16.09.26 - 22:06
|
Gossamer Bio Appoints Greg Ciongoli to Board of Directors (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.
Mr. Ciongoli has served as the Founder and Managing Partner of Adiumentum Capital Management, a Boston-based investment firm, since April 2024. Prior to Adiumentum, he was a Partner at the Baupost Group, where he worked on a broad range of public and private equity investments. Mr. Ciongoli also serves on the boards of directors of REGENXBIO Inc., Zymeworks, Inc. and Atara Biotherapeutics, Inc. He is actively involved in a number of local not-for-profit organizations. Mr. Ciongoli graduated from Princeton Univers...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
